United Kingdom



BRIEF-Glenmark Pharma gets FDA nod for generic version of skin disorder drug

* Receives ANDA approval for nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/g Source text: http://bit.ly/2faznIz Further company coverage: (Bengaluru newsroom)

3:51am BST

BRIEF-Hubei Jumpcan Pharmaceutical says controlling shareholder to transfer 12.4 pct stake in the co

* Says its controlling shareholder to transfer 100 million shares (12.4 percent stake) of the co to the controlling shareholder's wholly owned subsidiary

3:37am BST

BRIEF-Daiichi Sankyo completes 20.2 mln shares' buy-back for 50 bln yen

* Says it completes around 20.2 million shares' buy-back for approximately 50 billion yen as of Oct. 24

3:34am BST

U.S. FDA approves Merck's lung cancer drug as first-line treatment

Oct 24 Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment.

3:20am BST

BRIEF-Nuheara Ltd seeks trading halt

* Seeks trading halt pending release of an ASX announcement regarding a capital raising Source text for Eikon: Further company coverage:

2:26am BST
GlaxoSmithKline PLC 1,641.00p -1.05%
AstraZeneca PLC 4,851.00p -2.04%
Shire PLC 4,945.50p -2.13%


  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.